SK Licenses 1ST-104 for Parkinson Disease

Company SK Biopharmaceuticals / 1ST Biotherapeutics Event Type Exclusive Global License Modality Oral Dual-Kinase Small Molecule Asset 1ST-104 Target Type 2 LRRK2 and c-Abl (Dual Inhibitor) Disease Area Parkinson Disease Summary SK Biopharmaceuticals licensed exclusive global rights to 1ST-104, a preclinical oral Type 2 LRRK2…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Moonwalk Raises $70 Million for Adipose-Targeted RNAi
Neomorph – $100M Molecular Glue Financing